Cargando…

Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study

BACKGROUND: Surveys on prescription patterns for antipsychotics in the Scandinavian public health system are scarce despite the prevalent use of these drugs. The clinical differences between antipsychotic drugs are mainly in the areas of safety and tolerability, and international guidelines for the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroken, Rune A, Johnsen, Erik, Ruud, Torleif, Wentzel-Larsen, Tore, Jørgensen, Hugo A
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693495/
https://www.ncbi.nlm.nih.gov/pubmed/19445700
http://dx.doi.org/10.1186/1471-244X-9-24
_version_ 1782167959265869824
author Kroken, Rune A
Johnsen, Erik
Ruud, Torleif
Wentzel-Larsen, Tore
Jørgensen, Hugo A
author_facet Kroken, Rune A
Johnsen, Erik
Ruud, Torleif
Wentzel-Larsen, Tore
Jørgensen, Hugo A
author_sort Kroken, Rune A
collection PubMed
description BACKGROUND: Surveys on prescription patterns for antipsychotics in the Scandinavian public health system are scarce despite the prevalent use of these drugs. The clinical differences between antipsychotic drugs are mainly in the areas of safety and tolerability, and international guidelines for the treatment of schizophrenia offer rational strategies to minimize the burden of side effects related to antipsychotic treatment. The implementation of treatment guidelines in clinical practice have proven difficult to achieve, as reflected by major variations in the prescription patterns of antipsychotics between different comparable regions and countries. The objective of this study was to evaluate the practice of treatment of schizophrenic patients with antipsychotics at discharge from acute inpatient settings at a national level. METHODS: Data from 486 discharges of patients from emergency inpatient treatment of schizophrenia were collected during a three-month period in 2005; the data were collected in a large national study that covered 75% of Norwegian hospitals receiving inpatients for acute treatment. Antipsychotic treatment, demographic variables, scores from the Global Assessment of Functioning and Health of the Nation Outcome Scales and information about comorbid conditions and prior treatment were analyzed to seek predictors for nonadherence to guidelines. RESULTS: In 7.6% of the discharges no antipsychotic treatment was given; of the remaining discharges, 35.6% were prescribed antipsychotic polypharmacy and 41.9% were prescribed at least one first-generation antipsychotic (FGA). The mean chlorpromazine equivalent dose was 450 (SD 347, range 25–2800). In the multivariate regression analyses, younger age, previous inpatient treatment in the previous 12 months before index hospitalization, and a comorbid diagnosis of personality disorder or mental retardation predicted antipsychotic polypharmacy, while previous inpatient treatment in the previous 12 months also predicted prescription of at least one FGA. CONCLUSION: Our national survey of antipsychotic treatment at discharge from emergency inpatient treatment revealed antipsychotic drug regimens that are to some degree at odds with current guidelines, with increased risk of side effects. Patients with high relapse rates, comorbid conditions, and previous inpatient treatment are especially prone to be prescribed antipsychotic drug regimens not supported by international guidelines.
format Text
id pubmed-2693495
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26934952009-06-08 Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study Kroken, Rune A Johnsen, Erik Ruud, Torleif Wentzel-Larsen, Tore Jørgensen, Hugo A BMC Psychiatry Research Article BACKGROUND: Surveys on prescription patterns for antipsychotics in the Scandinavian public health system are scarce despite the prevalent use of these drugs. The clinical differences between antipsychotic drugs are mainly in the areas of safety and tolerability, and international guidelines for the treatment of schizophrenia offer rational strategies to minimize the burden of side effects related to antipsychotic treatment. The implementation of treatment guidelines in clinical practice have proven difficult to achieve, as reflected by major variations in the prescription patterns of antipsychotics between different comparable regions and countries. The objective of this study was to evaluate the practice of treatment of schizophrenic patients with antipsychotics at discharge from acute inpatient settings at a national level. METHODS: Data from 486 discharges of patients from emergency inpatient treatment of schizophrenia were collected during a three-month period in 2005; the data were collected in a large national study that covered 75% of Norwegian hospitals receiving inpatients for acute treatment. Antipsychotic treatment, demographic variables, scores from the Global Assessment of Functioning and Health of the Nation Outcome Scales and information about comorbid conditions and prior treatment were analyzed to seek predictors for nonadherence to guidelines. RESULTS: In 7.6% of the discharges no antipsychotic treatment was given; of the remaining discharges, 35.6% were prescribed antipsychotic polypharmacy and 41.9% were prescribed at least one first-generation antipsychotic (FGA). The mean chlorpromazine equivalent dose was 450 (SD 347, range 25–2800). In the multivariate regression analyses, younger age, previous inpatient treatment in the previous 12 months before index hospitalization, and a comorbid diagnosis of personality disorder or mental retardation predicted antipsychotic polypharmacy, while previous inpatient treatment in the previous 12 months also predicted prescription of at least one FGA. CONCLUSION: Our national survey of antipsychotic treatment at discharge from emergency inpatient treatment revealed antipsychotic drug regimens that are to some degree at odds with current guidelines, with increased risk of side effects. Patients with high relapse rates, comorbid conditions, and previous inpatient treatment are especially prone to be prescribed antipsychotic drug regimens not supported by international guidelines. BioMed Central 2009-05-16 /pmc/articles/PMC2693495/ /pubmed/19445700 http://dx.doi.org/10.1186/1471-244X-9-24 Text en Copyright © 2009 Kroken et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kroken, Rune A
Johnsen, Erik
Ruud, Torleif
Wentzel-Larsen, Tore
Jørgensen, Hugo A
Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study
title Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study
title_full Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study
title_fullStr Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study
title_full_unstemmed Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study
title_short Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study
title_sort treatment of schizophrenia with antipsychotics in norwegian emergency wards, a cross-sectional national study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2693495/
https://www.ncbi.nlm.nih.gov/pubmed/19445700
http://dx.doi.org/10.1186/1471-244X-9-24
work_keys_str_mv AT krokenrunea treatmentofschizophreniawithantipsychoticsinnorwegianemergencywardsacrosssectionalnationalstudy
AT johnsenerik treatmentofschizophreniawithantipsychoticsinnorwegianemergencywardsacrosssectionalnationalstudy
AT ruudtorleif treatmentofschizophreniawithantipsychoticsinnorwegianemergencywardsacrosssectionalnationalstudy
AT wentzellarsentore treatmentofschizophreniawithantipsychoticsinnorwegianemergencywardsacrosssectionalnationalstudy
AT jørgensenhugoa treatmentofschizophreniawithantipsychoticsinnorwegianemergencywardsacrosssectionalnationalstudy